Literature DB >> 31524497

Time in Range Is Associated with Carotid Intima-Media Thickness in Type 2 Diabetes.

Jingyi Lu1, Xiaojing Ma1, Yun Shen1, Qiang Wu2, Ren Wang3, Lei Zhang1, Yifei Mo1, Wei Lu1, Wei Zhu1, Yuqian Bao1, Robert A Vigersky4,5, Weiping Jia1, Jian Zhou1.   

Abstract

Background: Time in range (TIR) is an emerging metric of glycemic control and is reported to be associated with microvascular complications of diabetes. We sought to investigate the association of TIR obtained from continuous glucose monitoring (CGM) with carotid intima-media thickness (CIMT) as a surrogate marker of cardiovascular disease (CVD).
Methods: Data from 2215 patients with type 2 diabetes were cross-sectionally analyzed. TIR of 3.9-10.0 mmol/L was evaluated with CGM. CIMT was measured using high-resolution B-mode ultrasonography and abnormal CIMT was defined as a mean CIMT ≥1.0 mm. Logistic regression models were used to examine the independent association of TIR with CIMT.
Results: Compared with patients with normal CIMT, those with abnormal CIMT had significantly lower TIR (P < 0.001). The prevalence of abnormal CIMT progressively decreased across the categories of increasing TIR (P for trend <0.001). In a fully adjusted model controlling for traditional risk factor of CVD, each 10% increase in TIR was associated with 6.4% lower risk of abnormal CIMT. Stratifying the data by sex revealed that TIR was significantly associated with CIMT in males but not in females. In a subset of patients (n = 612) with complete data on diabetic retinopathy and albuminuria, we found that the relationship between TIR and CIMT remained to be significant, regardless of the status of microvascular complications. Conclusions: TIR is associated with CIMT in a large sample of patients with type 2 diabetes, suggesting a link between TIR and macrovascular disease.

Entities:  

Keywords:  Cardiovascular disease; Carotid intima-media thickness; Continuous glucose monitoring; Time in range; Type 2 diabetes

Mesh:

Substances:

Year:  2019        PMID: 31524497     DOI: 10.1089/dia.2019.0251

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  40 in total

1.  Estimation of Hemoglobin A1c from Continuous Glucose Monitoring Data in Individuals with Type 1 Diabetes: Is Time In Range All We Need?

Authors:  Chiara Fabris; Lutz Heinemann; Roy Beck; Claudio Cobelli; Boris Kovatchev
Journal:  Diabetes Technol Ther       Date:  2020-07       Impact factor: 6.118

2.  A Review of Continuous Glucose Monitoring-Based Composite Metrics for Glycemic Control.

Authors:  Michelle Nguyen; Julia Han; Elias K Spanakis; Boris P Kovatchev; David C Klonoff
Journal:  Diabetes Technol Ther       Date:  2020-03-04       Impact factor: 6.118

3.  Time in Range as a Research Outcome Measure.

Authors:  Joseph G Timmons; James G Boyle; John R Petrie
Journal:  Diabetes Spectr       Date:  2021-05-25

4.  Clinical Application of Time in Range and Other Metrics.

Authors:  Grazia Aleppo
Journal:  Diabetes Spectr       Date:  2021-05-25

5.  Associations of Time in Range and Other Continuous Glucose Monitoring-Derived Metrics With Well-Being and Patient-Reported Outcomes: Overview and Trends.

Authors:  Dominic Ehrmann; Lilli Priesterroth; Andreas Schmitt; Bernhard Kulzer; Norbert Hermanns
Journal:  Diabetes Spectr       Date:  2021-05-25

6.  Association of time in range with hemoglobin A1c, glycated albumin and 1,5-anhydro-d-glucitol.

Authors:  Mana Ohigashi; Keiko Osugi; Yoshiki Kusunoki; Kahori Washio; Satoshi Matsutani; Taku Tsunoda; Toshihiro Matsuo; Kosuke Konishi; Tomoyuki Katsuno; Mitsuyoshi Namba; Hidenori Koyama
Journal:  J Diabetes Investig       Date:  2020-11-15       Impact factor: 4.232

7.  Association of Body Fat Percentage with Time in Range Generated by Continuous Glucose Monitoring during Continuous Subcutaneous Insulin Infusion Therapy in Type 2 Diabetes.

Authors:  Yuting Ruan; Jiana Zhong; Rongping Chen; Zhen Zhang; Dixing Liu; Jia Sun; Hong Chen
Journal:  J Diabetes Res       Date:  2021-05-28       Impact factor: 4.011

8.  A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.

Authors:  Ildiko Lingvay; John B Buse; Edward Franek; Melissa V Hansen; Mette M Koefoed; Chantal Mathieu; Jeremy Pettus; Karolina Stachlewska; Julio Rosenstock
Journal:  Diabetes Care       Date:  2021-04-19       Impact factor: 19.112

9.  Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.

Authors:  Kyu Yong Cho; Hiroshi Nomoto; Akinobu Nakamura; Shinichiro Kawata; Hajime Sugawara; Jun Takeuchi; So Nagai; Kazuno Omori; Kazuhisa Tsuchida; Aika Miya; Ikumi Shigesawa; Kenichi Tsuchida; Shingo Yanagiya; Hiraku Kameda; Hiroki Yokoyama; Shinji Taneda; Yoshio Kurihara; Shin Aoki; Naoki Nishimoto; Tatsuya Atsumi; Hideaki Miyoshi
Journal:  J Diabetes Investig       Date:  2021-02-05       Impact factor: 4.232

10.  Time in Range Does Not Associate With Carotid Artery Wall Thickness and Endothelial Function in Type 1 Diabetes.

Authors:  Antonio Cutruzzolà; Martina Parise; Faustina B Scavelli; Milena Barone; Agostino Gnasso; Concetta Irace
Journal:  J Diabetes Sci Technol       Date:  2021-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.